The Patent Finder
AT

Allogene Therapeutics, Inc.

First filing 2017
OverviewNotableFeesChangesFamiliesPatent listSources & methods

22 patents currently held

2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jun 2036. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2036
Next term end
18
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 13, 2026
    The maintenance fee for DLL3 Targeting Chimeric Antigen Receptors and Binding Agents (US 11,673,953) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
  • 1 fee due Feb 22, 2027
    The maintenance fee for Antibodies Against 4G7-DERIVED Chimeric Antigen Receptors (US 11,732,041) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
  • 2 fees due Apr 10 to 17, 2027 · next Apr 10
  • 1 fee due Aug 13, 2027
    The maintenance fee for Polynucleotides Encoding Rituximab-Resistant Chimeric Antigen Receptors (US 11,896,617) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

What they patent

The 5 largest of its 18 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 11,072,644Inhibitory Chimeric Antigen Receptors
In force
 · High confidence
In forceHigh confidence
US 12,104,188Modified CASPASE-9 Polypeptides and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 11,326,156Modified CASPASE-9 Polypeptides and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,790,603Modified CASPASE-9 Polypeptides and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,447,178Method of Treatment Using ANTI-CD19 Rituximab-Resistant Chimeric Antigen Receptors
In force
 · Medium confidence
In forceMedium confidence
US 11,673,953DLL3 Targeting Chimeric Antigen Receptors and Binding Agents
In force
 · High confidence
In forceHigh confidence
US 12,606,623DLL3 Targeting Chimeric Antigen Receptors and Binding Agents
In force
 · High confidence
In forceHigh confidence
US 12,163,169Inducible Chimeric Cytokine Receptors
In force
 · High confidence
In forceHigh confidence
US 11,786,553Chimeric Cytokine Receptors Bearing a PD-1 Ectodomain
In force
 · High confidence
In forceHigh confidence
US 12,528,856Chimeric Cytokine Receptors Comprising TGF Beta Binding Domains
In force
 · High confidence
In forceHigh confidence
10 of 22 patents shown.
Pro members see all 22.
Pro members: see all 22 patents
Also on record, not counted in the 22: 2 patents in force now held by others · 37 applications pending · 9 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited